Trial Profile
Safety and Efficacy of BIO-101 Oral Administration to Patients Suffering From Age-related SARcopenia, Including Sarcopenic Obesity, Aged ≥65 Years and at Risk of Mobility Disability (SARA-INT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2023
Price :
$35
*
At a glance
- Drugs Sarconeos (Primary)
- Indications Muscular atrophy; Obesity
- Focus Proof of concept; Therapeutic Use
- Acronyms SARA INT
- Sponsors Biophytis
- 27 Mar 2023 According to a Biophytis media release, data from this study presented at the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR).
- 27 Jun 2022 According to a Biophytis media release, results of this trial will be presented at the 15th International SCWD Congress (Society on Sarcopenia, Cachexia & Wasting disorders).
- 04 Oct 2021 According to a Biophytis media release, further analyses, e.g. on correlations between clinical endpoints and other parameters, biomarkers and actimetry are ongoing and will be communicated later in scientific congresses.